Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple supplement soften thyroid nodules?

NCT ID NCT06736015

Disease control Sponsor: Regina Elena Cancer Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This trial tests whether a daily supplement containing myo-inositol and selenium can reduce the size and firmness of thyroid nodules that are considered indeterminate—meaning they have a low but not zero chance of being cancerous. Adults with such nodules will be randomly assigned to take the supplement for six months or to receive no treatment. Researchers will compare ultrasound and elastography measurements, as well as cell growth markers, between the two groups to see if the supplement has a beneficial effect.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A dietary supplement containing myo-inositol 600 mg and selenium 83 mcg, taken as one tablet daily for six months.
What this could lead to
If it works, this supplement could offer a non-surgical way to manage indeterminate thyroid nodules, potentially reducing the need for repeat biopsies or surgery.
What could go wrong
This is a small pilot study, so results may not be conclusive. The supplement may not change nodule size or firmness, and its effect on cancer risk is unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult (\>18 years old), * both sexes, * patients presenting thyroid nodules classified as TIR 3A, based on cytological evaluation on sample from the first fine needle aspiration (FNA), * written Informed consent, * Patients with appropriate material for subsequent immunocytochemical analysis of Ki-67 and PCNA Exclusion Criteria: * Patients with diagnosed thyroid malignancies of cytological diagnosis other than TIR3A * pathological levels of the thyroid stimulating hormone (TSH) which required L-Thyroxine treatment starting * pregnancy and/or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Thyroid nodule are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Thyroid Nodule

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Thyroid nodule

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Regina Elena National Cancer Institute

    RECRUITING

    Rome, 00144, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.